The Moscow Exchange decided to list the shares of Artgen Biotech (ex. Human Stem Cell Institute, MOEX: ISKJ).
On August 10, 2023, the Moscow Exchange decided to list Artgen Biotech’s shares in the “second level” securities section. Also, from August 18, the ticker of Artgen Biotech’s shares will be changed from ISKJ to ABIO. Listing will increase the investment attractiveness of the Company and expand the circle of potential investors.
There are three listing levels on the Moscow Exchange. The higher the level in which an asset is listed, the higher the reliability of the instrument and the lower the risk of depreciation, so the shares are easier to buy and sell. Levels I and II are called quotation lists. The securities listed here are available to all traders without restrictions. Previously, Artgen Biotech’s shares were traded as “non-listed stock” on the Moscow Exchange. Such shares are unavailable to the broad audience of investors, access is limited to qualified investors and investors who had passed testing.
“According to publicly available data, there are currently more than 25 million individual accounts on the Moscow Exchange, of which about 2.4 million are unqualified investors who have successfully passed the testing, and another 550 thousand are qualified investors,” comments Dmitry Krasotkin, Artgen Biotech’s investment director. Based on these data, the listing increases Artgen’s potential investor base by more than 8 times.”
In July 2023, the Human Stem Cell Institute (HSCI) changed its name to Artgen Biotech due to rebranding aimed at making the company’s activities, strategy, and values clearer to the public and a wider range of investors.
Artgen Biotech is a biotechnology company whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, diagnostics, and prevention methods that provide new means to combat socially significant and orphan diseases that are more effective than the existing ones. The group includes companies of different development stages, from seed to early growth and maturity, as well as companies forming a biotech development ecosystem within the group.
Artgen Biotech is a strategic investor in industries that improve the efficiency and quality of medical care. The Company is developing an internal ecosystem to accelerate biotech companies and commercialize their developments.
The company was founded in 2003. Since 2009, it has been an issuer at the Moscow Exchange Innovation and Investment Market.